NWBO Northwest Biotherapeutics, Inc.
Financings ·
Northwest Biotherapeutics signed a $4.9 million convertible note with a Yorkville fund on July 29, 2026. Net proceeds after original issue discount, a facility commitment fee and expenses are $4,655,000.
The company bought the UK manufacturer from a seller controlled by its chief executive. Payment is due in installments over two years.
The company cites issues tied to its Advent BioServices acquisition, including differences between UK GAAP and US GAAP. The notice gives no date for the annual report.
Common stock authorized rises from 1,700,000,000 to 2,600,000,000 shares. The company filed the amendment in Delaware on December 30, 2025.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $28.8 million | $34.9 million |
| Net income (loss) | -$60.2 million | -$83.8 million |
| Cash from operations | -$44.8 million | -$57.0 million |
| Cash and equivalents | $3.0 million | $2.2 million |
Our latest story on this, dated Jul 31, 2026: "Northwest Biotherapeutics registers 40,325,000 shares tied to $4.9 million note". The story links the filing or release it is based on. Read the story.
Northwest Biotherapeutics, Inc. trades under the ticker NWBO on OTC.
Northwest Biotherapeutics, Inc. is listed on OTC.
The SEC Central Index Key (CIK) for Northwest Biotherapeutics, Inc. is 1072379. Its filings are on SEC EDGAR.
1,705,637,993 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-14.
Our directory records Northwest Biotherapeutics, Inc. under United States.
Our directory classifies Northwest Biotherapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Northwest Biotherapeutics, Inc. is US66737P6007.
aibio.space lists Northwest Biotherapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Northwest Biotherapeutics, Inc. reported a net loss of $60.2 million for the fiscal year ended Dec 31, 2025, and used $44.8 million of cash in operations, per its annual report to the SEC.
$28.8 million in the fiscal year ended Dec 31, 2025, per its annual report.
$595,000 in cash at Jun 30, 2026, per its 10-Q.
Our latest story on Northwest Biotherapeutics, dated Jul 31, 2026: "Northwest Biotherapeutics registers 40,325,000 shares tied to $4.9 million note". Northwest Biotherapeutics signed a $4.9 million convertible note with a Yorkville fund on July 29, 2026. Net proceeds after original issue discount, a facility commitment fee and expenses are $4,655,000. Source.
Our latest financing story, dated Jul 31, 2026: "Northwest Biotherapeutics registers 40,325,000 shares tied to $4.9 million note". Northwest Biotherapeutics signed a $4.9 million convertible note with a Yorkville fund on July 29, 2026. Net proceeds after original issue discount, a facility commitment fee and expenses are $4,655,000. Source.
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.03,5.07,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio